Replies to post #7656 on BioCorRx Inc. (BICX)

[Pip611]

This is from the investor presentation on the BICX web site. I recommend you read it in its entirety and the fact sheet.

http://www.biocorrx.com/news-media/presentations

Alkermes Vivitrol injection has many drawbacks as reported
by consumers and physicians – very painful, very
deep IM injection (gluteus), large gauge needle
and large volume injection (4ml), requires
inefficient storage – yet sales continue to
skyrocket due to strong demand

BioCorRX Naltrexone Based Injectable
• Company partnered with TheraKine to
complete development of a new injectable
version of naltrexone using underlying
patented and patent pending technology
• Utilizing TheraKine’s patented micro-delivery
technology
• May be delivered subcutaneously (SQ) or
intramuscularly (IM) in smaller muscle (deltoid)
• May use small gauge needle
• Less volume (under 2ml)
• May not need to be refrigerated
• May be much less painful
• May last longer
• Ability to sub-license – interest already expressed
by third parties